Omnia Health is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Leinco partners with LJI to develop novel COVID-19 diagnostic tools

Gallery-Leinco partners with LJI to develop novel COVID-19 diagnostic tools

La Jolla Institute for Immunology (LJI), one of the leading research organisations dedicated to studying the immune system recently announced that it has signed a licensing agreement with Leinco Technologies, Inc., a developer and manufacturer of leading-edge recombinant proteins, antibodies, and conjugates. Leinco also provides custom manufacturing services to the diagnostic and biopharmaceutical industries to leverage proprietary COVID-19 antibodies developed at LJI.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.